Clinical Trial: A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Autoimmune Hemolytic Anemia
Study Type: INTERVENTIONAL
Official Title: The Safety and Efficacy of YTS109 Cell for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy
Brief Summary:
This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study.The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 STAR-T cell therapy in patients with autoimmune hemolytic anemia who have failed ?3 lines of therapy.The objective is to evaluate the safety, preliminary efficacy, pharmacokinetics/pharmacodynamics (PK/PD), and immune cell reconstitution characteristics of YTS109 cell therapy in Multi-rAIHA subjects…
Read more